drugset / Trial / NCT00905164

Topiramate 25 mg Capsules Under Fasting Conditions

NCT00905164

Phase 1 Completed 24 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to compare the rate and extent of absorption of topiramate 25 mg capsules (test) versus Topamax® (reference) administered as 2 x 25 mg capsules under fasting conditions.

Timeline

Start
2002-06
Primary completion
2002-06
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Topiramate Small molecule 50 mg

Indications

No indication recorded.